#1++ adapthealth Investor Presentation May 2020 + + +#2Disclaimer Disclaimers and Other Important Information This presentation (this "Presentation") is for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential investment in AdaptHealth Corp. ("AdaptHealth" or the "Company") and for no other purpose. The information contained in this Presentation does not purport to be all inclusive. The data contained herein is derived from various internal and external sources. The information contained in this Presentation is not, and should not be assumed to be, complete and does not present all the information that investors may require or desire in considering an investment in the Company. It is not intended to form the basis of any investment decision or any other decision in respect of the Company. AdaptHealth (as well as its respective directors, officers and stockholders) makes, and each of hereby expressly disclaims, any representations or warranties, express or implied, as to the reasonableness of the assumptions made in this Presentation or the accuracy or completeness of any projections or modeling or any other information contained in this Presentation. AdaptHealth shall have any liability for any representations, express or implied, contained in, or omissions from, this Presentation or any other written or oral communication communicated to the recipient in the course of the recipient's evaluation of AdaptHealth. Nothing contained within this Presentation is or should be relied upon as a promise or representation as to the future. AdaptHealth does not assume any obligation to provide the recipient with access to any additional information or to update the information in this Presentation. Investors should not construe the contents of this Presentation, or any prior or subsequent communications from or with the Company or its representatives as investment, legal or tax advice. No securities commission or securities regulatory authority or other authority in the United States or any other jurisdiction has in any way passed upon the merits of a potential investment in AdaptHealth or the accuracy or adequacy of this Presentation. Forward Looking Statements This investor presentation includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics, projections of market opportunity and expectations, the Company's acquisition pipeline and the impact of the recent coronavirus (COVID-19) pandemic and our response to it. These statements are based on various assumptions and on the current expectations of Company management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including the outcome of judicial and administrative proceedings to which the Company may become a party or governmental investigations to which the Company may become subject that could interrupt or limit the Company's operations, result in adverse judgments, settlements or fines and create negative publicity; changes in the Company's clients' preferences, prospects and the competitive conditions prevailing in the healthcare sector; and the impact of the recent coronavirus (COVID-19) pandemic and the Company's response to it. A further description of such risks and uncertainties can be found in the Company's filings with the Securities and Exchange Commission. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company presently knows or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect the Company's expectations, plans or forecasts of future events and views as of the date of this presentation. The Company anticipates that subsequent events and developments will cause the Company's assessments to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's assessments as of any date subsequent to the date of this presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements. Market and Industry Data Industry and market data used in this Presentation is unaudited and have been obtained from third-party industry publications and sources as well as from research reports prepared for other purposes. AdaptHealth has not independently verified the data obtained from these sources and cannot assure you of the data's accuracy or completeness. This data is subject to change and cannot always be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other limitations and uncertainties inherent in any statistical survey of market or industry data. You are cautioned not to give undue weight to such industry and market data. Non-GAAP and Other Financial Information This Presentation includes references to financial measures that are calculated and presented on the basis of methodologies other than in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP"), including EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex. AdaptHealth defines EBITDA as net income (loss) attributable to AdaptHealth Corp., plus net income attributable to noncontrolling interests, interest expense (income), income tax expense (benefit), and depreciation. AdaptHealth defines Adjusted EBITDA as EBITDA (as defined above), plus loss on extinguishment of debt, equity-based compensation expense, transaction costs, severance, and similar items of expense (income). AdaptHealth defines Adjusted EBITDA less Patient Equipment Capex as Adjusted EBITDA (as defined above) less patient equipment acquired during the period without regard to whether the equipment was purchased or financed through lease transactions. EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex should not be considered as measures of financial performance under U.S. GAAP, and the items excluded from EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex are significant components in understanding and assessing financial performance. Accordingly, these key business metrics have limitations as an analytical tool. They should not be considered as an alternative to net income or any other performance measures derived in accordance with U.S. GAAP or as an alternative to cash flows from operating activities as a measure of AdaptHealth's liquidity. No Offer or Solicitation This Presentation and any oral statements made in connection with this Presentation do not constitute an offer to sell, or a solicitation of an offer to buy, or a recommendation to purchase, any securities in any jurisdiction, or the solicitation of any proxy, vote, consent or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of any securities in any jurisdiction where, or to any person to whom, such offer, solicitation or sale may be unlawful under the laws of such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. ++ adapthealth 1#3Transaction Summary AdaptHealth has agreed to acquire two highly strategic and complementary recurring revenue supply businesses that are expected to be significantly accretive to growth, earnings and cash flow Solara Medical Supplies, LLC ("Solara") is the largest independent distributor of continuous glucose monitors (CGMs) and offers a comprehensive suite of diabetes management products Transformative transaction that will establish AdaptHealth as a leader in the fast growing diabetes management vertical Accretive to growth and highly synergistic with AdaptHealth's sleep therapy business and resupply capabilities Enhances AdaptHealth's strategic value to payors and advances connected health strategy Successful standalone platform with a best-in-class management team to drive organic and inorganic growth ActivStyle, Inc. ("ActivStyle") is a leading DTC distributor of incontinence products and related home medical supplies High quality business that accelerates growth, adds critical mass, and increases synergy capture within AdaptHealth PCS Current ActivStyle CEO will lead a supply division within AdaptHealth PCS Existing and new investors and lenders have committed to financing the transactions at attractive terms with a balanced mix of debt and equity Funding will support AdaptHealth's ability to execute on its robust growth pipeline ++ adapthealth 2#4Transaction Summary (continued) Purchase Consideration Financing Sources Financial Highlights Timing Solara purchase price of $425 million $362.5 million in cash $62.5 million in common stock issued to current owners including Linden Capital Management ActivStyle purchase price of $62 million paid in cash Funded with a balanced mix of debt and equity on attractive terms, including commitments from new and existing equity investors and lenders, supporting future growth ■ Committed debt financing from core lender group for a $240 million incremental Term Loan A $287.5 million in equity to be issued at a weighted average price of $14.18 per share $225 million in common and non-voting stock from One Equity Partners and Deerfield Management $62.5 million in common stock issued to Solara owners Expected to be significantly accretive to growth, earnings and cash flow in the first full year Transactions expected to contribute Adjusted EBITDA and EBITDA less Patient Equipment Capex of approximately $60 million and $55 million, respectively, in 2021 Includes expected run-rate cost synergies of approximately $7 million ■ Total Pro Forma LTM net leverage at close of approximately 2.9x1 Expected to close during Q3 2020 1. Includes full year impact of acquisitions and expected run-rate cost synergies adapthealth 13#5Transactions Advance AdaptHealth's Strategic Vision Today Leading Diversified Provider of HME Pro Forma Leading Provider of HME and Supply Solutions Our Goal Leading Provider of Connected Health Solutions Best-in-class technology platform National footprint with density in attractive markets Broad portfolio with minimal competitive bidding risk ■ Significant experience acquiring and integrating HME and Supply businesses Leader in sleep and diabetes, two of the fastest growing segments Long term, recurring, non- discretionary products; meaningful overlap across patient base Complex and service intensive, which plays to our strengths " Significant scale, and highly diversified Integrated, condition specific product suites Real time, actionable data to drive cost and outcome improvement Value-add partner to payors, providers and patients Move from fee for service to fee for value We enable complex care in the home, and are playing an increasing role in health management ++ adapthealth 4#6Compelling Industrial Logic for Acquisitions E Adds high quality, market leading platform assets, with management talent to further scale these business units Leans into core competencies - resupply, technology advantages, payors and referral relationships, field sales Increases exposure to relevant, high-cost categories for payors, with above market growth Further increase scale and diversify AdaptHealth's revenue stream, with a focus on recurring revenue Connected devices further our evolution from an HME provider to a chronic care management company Financially compelling - highly accretive with meaningful synergies ++ adapthealth 5#7Solara Overview SOLARA™ MEDICAL SUPPLIES Leader in diabetes management and the largest independent direct-to-patient distributor of CGMs $225mm est. run-rate Revenue 40,000+ active patients 300+ employees 25+ field sales 4 completed acquisitions 2002 founded, HQ in Chula Vista, CA Market Leader in a High Growth Segment Leader in diabetes management and the largest independent direct-to-patient distributor of CGMs CGM adoption is ramping rapidly, and drives long term, recurring resupply revenue Flexible 'One-Stop-Shop' Capabilities Comprehensive line of diabetes management supplies; preferred partner to CGM & insulin pump manufacturers Certified and credentialed to serve patients nationally, through DME or Rx channel (retail or national mail-order) Diverse and growing referral base, and broad in-network commercial and government payor coverage Platform Asset for Growth Best-in-class management team that will continue to lead the business post acquisition Well invested and scalable platform to support ongoing organic and inorganic growth within Adapt Highly synergistic with our resupply capabilities and integrates well with our core technology platform ++ adapthealth 6#8Diabetes Market Overview Diabetes Overview Diabetes is the most costly chronic disease in the US, with medical costs and lost productivity reaching $327 billion annually $1 out of every $7 healthcare dollars is spent treating diabetes or a complication of the disease ■ The number of diagnosed cases has doubled since 2000; approximately 34 million Americans have diabetes, while 88 million have developed prediabetes U.S. Diabetes Device Market ■ CGM technology has seen rapid adoption among diabetics due to innovative and easy to use new products and broadening reimbursement US Diabetes Device Market (in $bn) $2.1 CGM Market CAGR: -18% $3.4 $1.6 Insulin Pump Market CAGR: ~12% $2.2 12.1 2x Case Growth since 2000 25.3 34.2 million diabetics including undiagnosed 88 million pre-diabetics 2000 2002 2004 2006 2008 2010 2012 2014 2016 2018 Diagnosed diabetes cases (millions) Source: CDC, ADA, Wall Street Research, Solara Management, US Pharmacist ++ adapthealth 2019E 2022P 2019E Domestic Device Penetration Type 1 รพอว Pumps Patient count in millions; Percentages shown reflect device penetration 1.8 2.0 2022P Insulin intensive Type 2 5.6 5.9 74% 42% 10% 42% 2019E 2024P 2019E 2024P 1.8 2.0 5.6 5.9 44% 32% 8% 2019E 2024P 2019E 15% 2024P 7#9Comprehensive Diabetes Management Portfolio Solara offers a comprehensive suite of options for the effective management of diabetes, including CGMs, pumps, and ancillary supplies from all manufacturers Category & Representative Products Continuous DEXCOM Glucose Monitors 110 " ☐ Description Small sensor placed under the skin sends glucose levels to transmitter to monitor and display in real-time Increasingly the standard for effective blood glucose management Top Manufacturers Dexcom® Medtronic Abbott Insulin Pump Therapy Other Diabetes Supplies ++ adapthealth ONE TOUCH Microlet ◉ Device delivers small doses of continuous insulin and variable amounts during a meal Excellent alternative to syringes with more precise and dynamic dosing Includes other supplies like glucose meters, test strips, lancets, syringes, alcohol swabs, adhesives, and pen tip needles Insulet Corporation Medtronic valeritas TANDEM DIABETES CARE Abbott ACCU-CHEK LIFESCAN Johnson-Johnson company Roche smith&nephew 8#10One-Stop-Shop for All Constituents Solara covers the distribution market from all angles with a comprehensive approach to products, services, and sales strategy Provider Refers patient to manufacturer or distributor Referrals Can refer to Solara for DME or Rx, simplifying distributor decision Referrals Manufacturer Services patient directly or refers to distributor Distribution is not a core competency, resulting in increased outsourcing Referrals SOLARA MEDICAL SUPPLIES Multipronged sales strategy, marketing directly to providers, manufacturers, consumers, and payors Ability to serve patients through DME or Rx channel simplifies process for providers and patients DTC Marketing Order Placed Ships Order Patient ++ adapthealth Referred to Solara from provider, manufacturer, or Solara DTC marketing Can utilize either DME or Rx benefit Reorder Claims Submission Payments Receives claim and pays distributor according to contract Managed Markets team develops and expands payor relationships Payor/PBM 6#11ActivStyle Overview ActivStyle Your Medical Supply Advocate Leading direct-to-consumer ("DTC") supplier of incontinence and urological supplies + $60mm est. Revenue 90% recurring Revenue +~65,000 active patients. + 900+ payor contracts + 17 locations, with national distribution +1997 founded, HQ in Minneapolis, MN. Market Leader in an Attractive Niche Leader in DTC incontinence (~80% of revenue) and urological supplies, together a $3+ billion market Consumable products for chronically ill patients drives significant recurring revenue Patient preference for the convenience and discretion of home delivery continues to drive DTC growth Purpose-Built DTC Supply Platform Comprehensive product offering, including private label, and strong manufacturer relationships Established brand, successful lead-gen engine, and efficient, technology enabled fulfillment and revenue cycle capabilities Highly Synergistic Complements and adds critical mass to incontinence and urology business lines acquired in the PCS transaction Highly synergistic with AdaptHealth's resupply capabilities and integrates well with core technology platform Best-in-class management team that will continue to lead the business post acquisition ++ adapthealth 10#12Acquisitions Directly Aligned with Our Core Strengths ++ adapthealth Technology Infrastructure Leverages current tech infrastructure (e.g. Brightree); enables relatively quick synergizing of complex acquisitions Fulfillment Logistics O CGM is strong fit with our CPAP resupply capabilities and claims processing engine Patient Base Significant cross sell opportunities identified - many poly-chronic patients Payor Relationships ■Contracting advantages and national presence Sales Channel Broadens the aperture for our referral sources; leverages our 200+ field sales across complementary health system and physician call points Data & Analytics Additional connected devices enhance our value proposition 11#13Estimated Long-Term Growth Rates Our solutions play an important role in managing these chronic diseases in home Healthcare and Lost Chronic Disease Productivity Costs ($bn) AdaptHealth Product Product Line PF 2019 Net Revenue less BD Estimated Long-Term Growth Rates (in $bn) (in $mm) CGM, Insulin Diabetes $327 Respiratory $128 3.0-5.0% Pumps, Test Strips Heart Disease & $322 Oxygen, Supplies Stroke | Sleep 340 7.0-9.0% Obstructive Sleep $150 СРАР, ВІРАР HME 111 2.0-4.0% Apnea Obesity $147 PAP, Mobility, Supplies Diabetes 189 10.0-12.0% COPD $49 Oxygen, NIV Other Supply 248 2.0 - 4.0% Total $1,016 5.0 - 7.0% Adapt distributes products and provides services to patients with high-cost, chronic diseases Source: American Diabetes Association, CDC, American Association of Sleep Medicine ++ adapthealth Assuming 1-2% share capture, potential to grow at 7-10% organically 12#14High Value Solutions that Enhance Our Scale 1,800 1,600 1,400 LTM Pro Forma Unique Patients Serviced (in thousands) ■ActivStyle Solara Adapt Revenue ($ in millions) 1,710 ■ ActivStyle Solara ■ Adapt¹ $1,200 $1,088 $1,000 1,181 1,200 1,137 1,010 1,039 $800 1,000 895 850 795 800 $600 600 480 501 400 200 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2017 2018 2019 2020 1. Based on midpoint of 2020E management guidance presented during Q1 2020 earnings call ++ adapthealth $400 $193 $174 $200 $345 $529 2016 2017 2018 2019 2020 PF 13#15Pro Forma Adapt is Significantly Diversified Adapt¹ Diabetes 2% Respiratory 16% PF Adapt² Diabetes 19% Respiratory 3 13% Diversifies Product Offerings With Scale Diabetes Business Other Supply 24% Sleep 44% HME 14% One-off Sale 16% Business Mix Now 85%+ Recurring Sale or Rental Rental 36% Recurring Sale 47% Highly Diversified Payor Mix Tricare 1% Other 15% FFS Medicare 27% Commercial 39% Managed Medicare 9% Medicare (Incl. Managed Medicaid) 8% Other Supply 4 24% Rental 28% HME 11% Sleep 34% One-off Sale 14% Recurring Sale 58% Tricare 5% Other 13% FFS Medicare 22% Managed Medicare Commercial 40% 7% Medicaid (Incl. Managed Medicaid) 13% Based on CY 2019 net revenue less bad debt including PCS, AHC, and HL on a PF basis 2. Includes Solara, ActivStyle 3. Includes Oxygen / Vents 4. Includes Urology, Ostomy, Wound Care, Incontinence, Other (Ortho/Breast Pump / Enteral) 1. ++ adapthealth 14#16Positioned to Lead the Shift to Connected Healthcare Patients + Simplify Health Management + Encourage Compliance + Drive Better Engagement + Improve Outcomes 帕 ++ adapthealth $ Payors and Providers + Monitor Treatment Plan Effectiveness + Drive Early Interventions + Reduce Hospitalizations + Improve Outcomes Connected y Blood Pressure NIV CPAP Devices CGM Oximeter Scales ++ adapthealth 15#17Case Study: Diabetic Patient on CGM and Sleep Therapy Illustrative Diabetic Patient Needs AdaptHealth Platform + Allows the Company to monitor: CPAP CGM Pump Scale Real-time insulin levels Real-time information on sleep quality Weight fluctuation Patient data can be compared to a baseline and used to: Measure the effectiveness of social and clinical interventions (i.e. diet, weight loss and the impact of that on sleep and insulin levels) Identify risks that may require clinical intervention We estimate that a meaningful amount of our PAP patients may be a Type 1 or Type 2 diabetic ++ adapthealth 16#18Appendix + + +#191 Transaction Details Sources and Uses of Funds (in $mm) Incremental TLA Pro Forma FDSO Calculation (in mm) $240 Standalone FDSO1 77.8 One Equity Investment $190 One Equity Partners Shares 13.8 Sources Deerfield Investment $35 Incremental Deerfield Shares 2.5 Solara Shareholder Equity $63 Solara Shares 3.9 Total Sources $528 Total PF FDSO1 98.1 Purchase of Solara $425 Purchase of ActivStyle $62 Uses Est. fees, OID, and other exp. $12 Cash to Balance Sheet $29 Total Uses $528 Calculated using Treasury Stock Method for outstanding warrants and options. Share price of $16.65 as of 5/22/20; Excludes the impact of any earnouts ++ adapthealth 18#20Equity Investment Terms Investment Amount One Equity Partners $ 190.0 million $35.0 million Non-Voting Deerfield Mgmt. Solara Shareholders Total $62.5 million $287.5 million Form of Equity Common Stock and Non-Voting Stock Common Stock Stock Price Per Share $13.75 $13.75 $16.00 $14.184 Premium (Discount) (13.8%) to 30 Day VWAP1 (13.8%) 0.3% (11.1%) Shares Issued 13.8mm 2.5mm 3.9mm 20.3mm Percentage of Pro 14.1% 2.6% 4.0% Forma FDSO2 Governance One board seat No change None Company has Other terms³ option to reduce investment amount by up to $50 million with proceeds from an equity offering pre-closing N/A N/A Pro Forma FDSO (98.1mm) is equal to current FDSO (77.8mm) as of 5/1/20+ One Equity Partners Shares (13.8mm) + Deerfield Management Shares (2.5mm) + Solara Shareholder Shares (3.9mm). Current FDSO assumes treasury stock method for outstanding warrants and options. Share price of $16.65 as of 5/22/20. Excludes the impact of any earnouts; For Deerfield reflects only newly issued shares 1. As of 5/22/20 2. 3. Common shares issued will have customary rights and lock-ups 4. Weighted average ++ adapthealth 19#21Thank You + + +